Querques Giuseppe, Merle Bénédicte M J, Pumariega Nicole M, Benlian Pascale, Delcourt Cécile, Zourdani Alain, Leisy Heather B, Lee Michele D, Smith R Theodore, Souied Eric H
Department of Ophthalmology - Hôpital intercommunal de Créteil - Université Paris Est Créteil, Créteil, France.
Department of Ophthalmology, New York University, New York, New York, United States of America.
PLoS One. 2016 Feb 22;11(2):e0149219. doi: 10.1371/journal.pone.0149219. eCollection 2016.
To evaluate the dynamic remodeling of drusen in subjects with unilateral neovascular age-related macular degeneration (AMD) receiving a three-year course of oral docosahexaenoic acid (DHA) or placebo.
Institutional setting.
Three hundred subjects with age-related maculopathy and neovascular AMD in the fellow eye were randomly assigned to receive either 840 mg/day DHA or placebo for 3 years. Main outcome measures of this post-hoc sub-group analysis were progression of drusen number, total diameter, and total area on fundus photography, and their association with DHA supplementation, socio-demographic and genetic characteristics.
Drusen progression was analyzed in 167 subjects that did not develop CNV (87 that received DHA and 80 that received placebo). None of the drusen remodeling outcomes were significantly associated with DHA supplementation. Total drusen diameter reduction in the inner subfield was significantly associated with age (older patients: r = -0.17; p = 0.003). Women showed a tendency to decreased total drusen diameter in the inner subfield with CFH polymorphism (p = 0.03), where women with TT genotype tended to have a greater reduction in drusen diameter than other genotypes (CC and CT). Drusen area in the inner subfield was more reduced in older patients (r = -0.17) and in women (p = 0.01). Drusen number showed no significant trends.
Dynamic drusen remodeling with net reduction in drusen load over three years was found in patients with exudative AMD in one eye and drusen in the other eye (study-eye). This reduction was correlated with increased age and female gender, and showed a tendency to be influenced by CFH genotype, but did not appear to be affected by DHA supplementation.
Controlled-Trials.com ISRCTN98246501.
评估单侧新生血管性年龄相关性黄斑变性（AMD）患者在接受为期三年的口服二十二碳六烯酸（DHA）或安慰剂治疗过程中玻璃膜疣的动态重塑情况。
机构设置。
300例年龄相关性黄斑病变且对侧眼为新生血管性AMD的患者被随机分配接受840毫克/天的DHA或安慰剂治疗3年。该事后亚组分析的主要结局指标为眼底摄影中玻璃膜疣数量、总直径和总面积的进展情况，以及它们与DHA补充、社会人口统计学和基因特征的关联。
对167例未发生脉络膜新生血管（CNV）的患者（87例接受DHA治疗，80例接受安慰剂治疗）的玻璃膜疣进展情况进行了分析。玻璃膜疣重塑的各项结果均与DHA补充无显著关联。内亚区玻璃膜疣总直径的减小与年龄显著相关（年龄较大的患者：r = -0.17；p = 0.003）。女性在携带CFH基因多态性时，内亚区玻璃膜疣总直径有减小的趋势（p = 0.03），其中TT基因型的女性玻璃膜疣直径减小幅度往往大于其他基因型（CC和CT）。内亚区玻璃膜疣面积在年龄较大的患者中减小得更多（r = -0.17），在女性中也减小得更多（p = 0.01）。玻璃膜疣数量未显示出显著趋势。
在一只眼患有渗出性AMD而另一只眼（研究眼）有玻璃膜疣的患者中发现了玻璃膜疣的动态重塑，且在三年间玻璃膜疣负荷净减少。这种减少与年龄增长和女性性别相关，并且显示出受CFH基因型影响的趋势，但似乎不受DHA补充的影响。
Controlled-Trials.com ISRCTN98246501。
